|
|
Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: A pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models |
Oliveras Ferrarós, Cristina
; Vázquez MartÃn, Alejandro
; Queralt, Bernardo
; Adrados, Manuel
; Ortiz, Rosa
; Cufà González, SÃlvia
; Hernández Yagüe, Xavier
; Guardeño, Raquel
; Báez, Luciana
; Martin Castillo, Begoña
; Pérez MartÃnez, Maria Carmen
; López Bonet, Eugeni
; Llorens Duran, Rafael de
; Bernadó, Luis
; Brunet i Vidal, Joan
; Menéndez Menéndez, Javier Abel
|
|
|
Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: A pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models |
Oliveras Ferrarós, Cristina
; Vázquez MartÃn, Alejandro
; Queralt, Bernardo
; Adrados, Manuel
; Ortiz, Rosa
; Cufà González, SÃlvia
; Hernández Yagüe, Xavier
; Guardeño, Raquel
; Báez, Luciana
; Martin Castillo, Begoña
; Pérez MartÃnez, Maria Carmen
; López Bonet, Eugeni
; Llorens Duran, Rafael de
; Bernadó, Luis
; Brunet i Vidal, Joan
; Menéndez Menéndez, Javier Abel
|
|
5 juny 2018 |
Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: A pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models |
Oliveras Ferrarós, Cristina
; Vázquez MartÃn, Alejandro
; Queralt, Bernardo
; Adrados, Manuel
; Ortiz, Rosa
; Cufà González, SÃlvia
; Hernández Yagüe, Xavier
; Guardeño, Raquel
; Báez, Luciana
; Martin Castillo, Begoña
; Pérez MartÃnez, Maria Carmen
; López Bonet, Eugeni
; Llorens Duran, Rafael de
; Bernadó, Luis
; Brunet i Vidal, Joan
; Menéndez Menéndez, Javier Abel
|
|
2011 |
Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: A pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models |
Oliveras Ferrarós, Cristina
; Vázquez MartÃn, Alejandro
; Queralt, Bernardo
; Adrados, Manuel
; Ortiz Duran, Maria Rosa
; Cufà González, SÃlvia
; Hernández Yagüe, Xavier
; Guardeño, Raquel
; Báez, Luciana
; Martin Castillo, Begoña
; Pérez MartÃnez, Maria Carmen
; López Bonet, Eugeni
; Llorens Duran, Rafael de
; Bernadó, Luis
; Brunet i Vidal, Joan
; Menéndez Menéndez, Javier Abel
|
|
12 setembre 2016 |
Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer |
Queralt, Bernardo
; Cuyà s, Elisabet
; Bosch Barrera, Joaquim
; Massaguer i Vall-llovera, Anna
; Llorens Duran, Rafael de
; Martin Castillo, Begoña
; Brunet i Vidal, Joan
; Salazar, Ramon
; Menéndez Menéndez, Javier Abel
|
|
|
Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer |
Queralt, Bernardo
; Cuyà s, Elisabet
; Bosch Barrera, Joaquim
; Massaguer i Vall-llovera, Anna
; Llorens Duran, Rafael de
; Martin Castillo, Begoña
; Brunet i Vidal, Joan
; Salazar, Ramon
; Menéndez Menéndez, Javier Abel
|
|
|
Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer |
Queralt, Bernardo
; Cuyà s, Elisabet
; Bosch Barrera, Joaquim
; Massaguer i Vall-llovera, Anna
; Llorens Duran, Rafael de
; Martin Castillo, Begoña
; Brunet i Vidal, Joan
; Salazar, Ramon
; Menéndez Menéndez, Javier Abel
|
|
5 juny 2018 |
Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer |
Queralt, Bernardo
; Cuyà s, Elisabet
; Bosch Barrera, Joaquim
; Massaguer i Vall-llovera, Anna
; Llorens Duran, Rafael de
; Martin Castillo, Begoña
; Brunet i Vidal, Joan
; Salazar, Ramon
; Menéndez Menéndez, Javier Abel
|
|
2012 |
Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment |
Oliveras Ferrarós, Cristina
; Massaguer i Vall-llovera, Anna
; Vázquez MartÃn, Alejandro
; Carrion Salip, Dolors
; Queralt, Bernardo
; Cufà González, SÃlvia
; Martin Castillo, Begoña
; Bosch Barrera, Joaquim
; Brunet i Vidal, Joan
; Llorens Duran, Rafael de
; Menéndez Menéndez, Javier Abel
|
|
|
Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment |
Oliveras Ferrarós, Cristina
; Massaguer i Vall-llovera, Anna
; Vázquez MartÃn, Alejandro
; Carrion Salip, Dolors
; Queralt, Bernardo
; Cufà González, SÃlvia
; Martin Castillo, Begoña
; Bosch Barrera, Joaquim
; Brunet i Vidal, Joan
; Llorens Duran, Rafael de
; Menéndez Menéndez, Javier Abel
|
|
|
Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment |
Oliveras Ferrarós, Cristina
; Massaguer i Vall-llovera, Anna
; Vázquez MartÃn, Alejandro
; Carrion Salip, Dolors
; Queralt, Bernardo
; Cufà González, SÃlvia
; Martin Castillo, Begoña
; Bosch Barrera, Joaquim
; Brunet i Vidal, Joan
; Llorens Duran, Rafael de
; Menéndez Menéndez, Javier Abel
|
|
5 juny 2018 |
Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment |
Oliveras Ferrarós, Cristina
; Massaguer i Vall-llovera, Anna
; Vázquez MartÃn, Alejandro
; Carrion Salip, Dolors
; Queralt, Bernardo
; Cufà González, SÃlvia
; Martin Castillo, Begoña
; Bosch Barrera, Joaquim
; Brunet i Vidal, Joan
; Llorens Duran, Rafael de
; Menéndez Menéndez, Javier Abel
|